Author: Ken Dropiewski

Microbot Medical Announce Strategic Addition to Scientific Advisory Board Appointment

Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience HINGHAM, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment to its Scientific Advisory Board (SAB), David C. Madoff, M.D. […]

Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on October 1, 2022 that were approved by the Compensation Committee of its Board of […]

InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth

Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as President and CEO; Will Serve as Consultant to Ensure Smooth Leadership Transition SAN FRANCISCO, Oct. 04, 2022 (GLOBE NEWSWIRE) — InCarda […]

Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting

Traditional Care: More than 50% Discharged From Hospital With Suboptimal Treatment Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with […]

Catheter Precision Files a Method-of-Use U.S. Patent Application for its VIVO™ Technology

MT. OLIVE, N.J. & CARLSBAD, Calif.–(BUSINESS WIRE)–Catheter Precision, Inc. (“Catheter Precision”), a medical device company focused on cardiac electrophysiology, announces the filing of a new U.S. patent application for its VIVO™ (View Into Ventricular Onset) technology, as it continues its focus on patent protection for VIVO. On September 12, 2022 privately […]

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today that it has commenced an underwritten public offering of $100 million of shares of its common stock. Rocket also […]

ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research LOS ANGELES–(BUSINESS WIRE)–ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of […]

Endotronix Celebrates 400th Implant of Cordella™ Pulmonary Artery Pressure Sensor for Proactive, Remote Heart Failure Management

Company also announces publication of the PROACTIVE-HF trial design rationale, the first global IDE trial for PA pressure-guided heart failure management, in the Journal of Cardiac Failure LISLE, Ill., Sept. 30, 2022 /PRNewswire/ — Endotronix, Inc., a privately-held digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced […]

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough CardiAMP® Cell Therapy […]